Serpins regulate coagulation and
inflammation, binding
serine proteases in suicide-inhibitory complexes. Target
proteases cleave the
serpin reactive center loop scissile P1-P1' bond, resulting in
serpin-
protease suicide-inhibitory complexes. This inhibition requires a near full-length
serpin sequence. Myxomavirus Serp-1 inhibits thrombolytic and thrombotic
proteases, whereas mammalian
neuroserpin (NSP) inhibits only thrombolytic
proteases. Both
serpins markedly reduce
arterial inflammation and plaque in rodent models after single dose infusion. In contrast, Serp-1 but not NSP improves survival in a lethal murine gammaherpesvirus68 (MHV68)
infection in
interferon γ-receptor-deficient mice (IFNγR(-/-)). Serp-1 has also been successfully tested in a Phase 2a clinical trial. We postulated that proteolytic cleavage of the reactive center loop produces active
peptide derivatives with expanded function. Eight
peptides encompassing predicted
protease cleavage sites for Serp-1 and NSP were synthesized and tested for inhibitory function in vitro and in vivo. In engrafted aorta, selected
peptides containing Arg or Arg-Asn, not Arg-Met, with a 0 or +1 charge, significantly reduced plaque. Conversely,
S-6 a hydrophobic
peptide of NSP, lacking Arg or Arg-Asn with -4 charge, induced early
thrombosis and mortality. S-1 and
S-6 also significantly reduced CD11b(+) monocyte counts in mouse splenocytes. S-1
peptide had increased efficacy in
plasminogen activator inhibitor-1
serpin-deficient transplants. Plaque reduction correlated with mononuclear cell activation. In a separate study, Serp-1
peptide S-7 improved survival in the MHV68
vasculitis model, whereas an inverse
S-7 peptide was inactive. Reactive center
peptides derived from Serp-1 and NSP with suitable charge and hydrophobicity have the potential to extend immunomodulatory functions of
serpins.